The division is actively involved in clinical, translational, and basic research. The clinical faculty participates in CARRA (the Childhood Arthritis and Rheumatology Research Alliance) the main national research group for collaborative research at a national level. They are involved in registry activity and several prospective, observational outcome trials. With Rosenkranz’s leadership, the division is also involved in pharmaceutical trials of novel agents for the treatment of rheumatology conditions in children. Torok’s research is focused on the inflammatory and profibrotic cytokines involved in pediatric scleroderma. She uses a translational approach by comparing these proteins in serum and skin biopsy specimens with clinical parameters of disease activity and damage in her pediatric scleroderma cohort. de Vallejo leads a basic research program on the immunobiology of aging and inflammatory syndromes. Canna uses genetic and functional insights from patients and model systems to find ways to subtype Systemic Inflammatory Response Syndrome (SIRS)/sepsis patients in diagnostically and therapeutically meaningful ways. Grant dollars to the division totaled $1,083,556 of which $985,381 represented direct dollars. Total grant dollars increased by 75% in 2017 when compared to the prior year.